Sugi Predict

Sugi Predict / Targets / MEN1

MEN1

Menin · O00255 · MEN1 on Sugi Atlas →

6,082,201 patent compounds predicted against MEN1, 3,128,493 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Reserpine Reserpine (SCHEMBL2589) 1.00 13/20
Daunorubicin Daunorubicin (SCHEMBL3041) 1.00 10/20
Carubicin Carubicin (SCHEMBL4201) 0.98 10/20
Chlortetracycline Chlortetracycline (SCHEMBL3841) 0.71 10/20
Chlortetracycline Chlortetracycline (SCHEMBL3842) 0.71 10/20
Demeclocycline Demeclocycline (SCHEMBL3252) 0.71 10/20
Demeclocycline Demeclocycline (SCHEMBL3253) 0.71 10/20
Chlortetracycline Chlortetracycline (SCHEMBL3110) 0.70 10/20
Chlortetracycline Chlortetracycline (SCHEMBL3111) 0.70 10/20
Epirubicin Epirubicin (SCHEMBL3165) 1.00 9/20
Doxorubicin Doxorubicin (SCHEMBL3242) 1.00 9/20
Doxorubicin Doxorubicin (SCHEMBL3243) 1.00 9/20
Idarubicin Idarubicin (SCHEMBL3750) 1.00 9/20
Zorubicin Zorubicin (SCHEMBL4023) 0.80 9/20
Zorubicin Zorubicin (SCHEMBL4024) 0.80 9/20
Phenazopyridine Phenazopyridine (SCHEMBL270) 0.77 9/20
Oxytetracycline Oxytetracycline (SCHEMBL2898) 0.70 9/20
Oxytetracycline Oxytetracycline (SCHEMBL2899) 0.70 9/20
SCHEMBL3446 SCHEMBL3446 0.62 9/20
Meclocycline Meclocycline (SCHEMBL3445) 0.59 9/20

Clinical trials — most relevant to MEN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment PHASE3UNKNOWN
Cinacalcet to Treat Familial Primary Hyperparathyroidism PHASE3COMPLETED
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors PHASE2COMPLETED
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome PHASE2NOT_YET_RECRUITING
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer PHASE1/PHASE2COMPLETED
Studies of Elevated Parathyroid Activity PHASE2COMPLETED
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma PHASE2COMPLETED
FTT PET/CT in Pancreatic Neuroendocrine Tumors PHASE1RECRUITING
Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 Database) nanNOT_YET_RECRUITING
Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation nanRECRUITING
Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients nanRECRUITING
Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) nanUNKNOWN
Study and Monitoring of Multiple Endocrine Neoplasia Type 1 nanRECRUITING
Type 1 Multiple Endocrine Neoplasia Cohort Study nanUNKNOWN
Natural History Study of Children and Adults With Medullary Thyroid Cancer nanRECRUITING
Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients nanRECRUITING
Study and Follow-up of Multiple Endocrine Neoplasia Type 1 nanRECRUITING
Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 nanACTIVE_NOT_RECRUITING
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients nanCOMPLETED
Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors nanCOMPLETED
EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors nanUNKNOWN
Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia nanUNKNOWN
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China nanENROLLING_BY_INVITATION
Genetic Evaluation of Families With Endocrine Cancers nanCOMPLETED
A New Method for Determining Gastric Acid Output Using a Wireless Capsule nanCOMPLETED
Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes nanCOMPLETED
18F-Fluorocholine PET/CT in Medullary Thyroid Cancer nanUNKNOWN
Study of Adrenal Gland Tumors nanCOMPLETED
Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients nanCOMPLETED
Observational Study on Thyroid Tumors and EvaLuation of the roLe of New pOntential Predictive/Prognostic Factors nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a MEN1 binder may also engage these)

ProteinNameSimilarity
Q0P5I0 — 1.000 Q0P5I0 →
A2SXS5 — 1.000 A2SXS5 →
Q9WVR8 — 1.000 Q9WVR8 →
O88559 — 0.998 O88559 →
Q8C190 — 0.982 Q8C190 →
Q9Y2B5 — 0.981 Q9Y2B5 →
Q496Y0 — 0.976 Q496Y0 →
Q69Z89 — 0.976 Q69Z89 →
Q17RQ9 — 0.976 Q17RQ9 →
P97260 — 0.976 P97260 →
Q9Z272 — 0.976 Q9Z272 →
Q8TBN0 — 0.975 Q8TBN0 →
Q5MNU5 — 0.975 Q5MNU5 →
A2RRU4 — 0.975 A2RRU4 →
Q9TUG2 — 0.975 Q9TUG2 →
Q66H91 — 0.974 Q66H91 →
Q0VF94 — 0.974 Q0VF94 →
Q92622 — 0.974 Q92622 →
Q8NFZ0 — 0.974 Q8NFZ0 →
Q4R4I0 — 0.974 Q4R4I0 →
Q9HCE6 — 0.973 Q9HCE6 →
P12755 — 0.973 P12755 →
Q8WVT3 — 0.973 Q8WVT3 →
TERF2IP Telomeric repeat-binding factor 2-interacting protein 1 0.973 landscape →
Q5XPI4 — 0.973 Q5XPI4 →
A2AWP8 — 0.973 A2AWP8 →
Q9H3S7 — 0.972 Q9H3S7 →
Q68EN5 — 0.972 Q68EN5 →
Q60698 — 0.972 Q60698 →
Q6NS60 — 0.972 Q6NS60 →